显示样式:     当前期刊: Nature Reviews Clinical Oncology    加入关注    导出
我的关注
我的收藏
您暂时未登录!
登录
  • Targeted therapies: Precision medicine for ATC — BRAF and MEK inhibition shows promise
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-17
    David Killock

    Targeted therapies: Precision medicine for ATC — BRAF and MEK inhibition shows promise Targeted therapies: Precision medicine for ATC — BRAF and MEK inhibition shows promise, Published online: 17 November 2017; doi:10.1038/nrclinonc.2017.181

    更新日期:2017-11-20
  • Targeted therapies: Precision medicine for ATC — BRAF and MEK inhibition shows promise
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    David Killock

    Targeted therapies: Precision medicine for ATC — BRAF and MEK inhibition shows promise Targeted therapies: Precision medicine for ATC — BRAF and MEK inhibition shows promise, Published online: 17 November 2017; doi:10.1038/nrclinonc.2017.181

    更新日期:2017-11-19
  • Immunotherapy: Nice to see you — evolving MHC I–peptide presentation
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-14
    Diana Romero

    Immunotherapy: Nice to see you — evolving MHC I–peptide presentationImmunotherapy: Nice to see you — evolving MHC I–peptide presentation, Published online: 14 November 2017; doi:10.1038/nrclinonc.2017.180

    更新日期:2017-11-14
  • Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-14
    Alexander Drilon, Zishuo I. Hu, Gillianne G. Y. Lai, Daniel S. W. Tan

    Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapesTargeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes, Published online: 14 November 2017; doi:10.1038/nrclinonc.2017.175NatureArticleSnippet(type=short-summary, markup=The receptor-tyrosine kinase RET has been identified as a potentially actionable driver of oncogenesis. Several multikinase inhibitors with activity against RET have been explored in the clinic, but have only modest efficacy in patients with thyroid cancers, mostly in those with RET mutations, or RET-rearranged lung cancers. Herein, the authors outline the aberrations in RET that contribute to tumorigenesis, review the current clinical data for inhibitors of this kinase, and discuss whether the limited clinical success achieved with these agents to date is attributable to the intractability of RET as a drug target or the lack of highly specific RET inhibitors., isJats=true)

    更新日期:2017-11-14
  • In the news
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-14
    Diana Romero

    In the newsIn the news, Published online: 14 November 2017; doi:10.1038/nrclinonc.2017.179

    更新日期:2017-11-14
  • Immunotherapy: Nice to see you — evolving MHC I–peptide presentation
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-14
    Diana Romero

    Immunotherapy: Nice to see you — evolving MHC I–peptide presentationImmunotherapy: Nice to see you — evolving MHC I–peptide presentation, Published online: 14 November 2017; doi:10.1038/nrclinonc.2017.180

    更新日期:2017-11-14
  • Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-14
    Alexander Drilon, Zishuo I. Hu, Gillianne G. Y. Lai, Daniel S. W. Tan

    Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapesTargeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes, Published online: 14 November 2017; doi:10.1038/nrclinonc.2017.175NatureArticleSnippet(type=short-summary, markup=The receptor-tyrosine kinase RET has been identified as a potentially actionable driver of oncogenesis. Several multikinase inhibitors with activity against RET have been explored in the clinic, but have only modest efficacy in patients with thyroid cancers, mostly in those with RET mutations, or RET-rearranged lung cancers. Herein, the authors outline the aberrations in RET that contribute to tumorigenesis, review the current clinical data for inhibitors of this kinase, and discuss whether the limited clinical success achieved with these agents to date is attributable to the intractability of RET as a drug target or the lack of highly specific RET inhibitors., isJats=true)

    更新日期:2017-11-14
  • In the news
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-14
    Diana Romero

    In the newsIn the news, Published online: 14 November 2017; doi:10.1038/nrclinonc.2017.179

    更新日期:2017-11-14
  • Immunotherapy: Nivolumab-induced alterations revealed
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-08
    Peter Sidaway

    Immunotherapy: Nivolumab-induced alterations revealed Immunotherapy: Nivolumab-induced alterations revealed, Published online: 08 November 2017; doi:10.1038/nrclinonc.2017.173

    更新日期:2017-11-08
  • Drug development for noncastrate prostate cancer in a changed therapeutic landscape
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-08
    Min Yuen Teo, Matthew J. O'Shaughnessy, Sean M. McBride, Herbert A. Vargas, Howard I. Scher

    Drug development for noncastrate prostate cancer in a changed therapeutic landscape Drug development for noncastrate prostate cancer in a changed therapeutic landscape, Published online: 08 November 2017; doi:10.1038/nrclinonc.2017.177

    更新日期:2017-11-08
  • Tumour heterogeneity and resistance to cancer therapies
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-08
    Ibiayi Dagogo-Jack, Alice T. Shaw

    Tumour heterogeneity and resistance to cancer therapies Tumour heterogeneity and resistance to cancer therapies, Published online: 08 November 2017; doi:10.1038/nrclinonc.2017.166 NatureArticleSnippet(type=short-summary, markup= The onset of acquired resistance to treatment is virtually inevitable in patients with solid tumours. In this Review, the authors describe the role of tumour heterogeneity in the development of acquired resistance, potential treatment strategies that take into account the heterogeneity of patient's tumours, and how a better understanding of tumour heterogeneity might improve the outcomes of patients. , isJats=true)

    更新日期:2017-11-08
  • Immunotherapy: Nivolumab-induced alterations revealed
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-08
    Peter Sidaway

    Immunotherapy: Nivolumab-induced alterations revealed Immunotherapy: Nivolumab-induced alterations revealed, Published online: 08 November 2017; doi:10.1038/nrclinonc.2017.173

    更新日期:2017-11-08
  • Drug development for noncastrate prostate cancer in a changed therapeutic landscape
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-08
    Min Yuen Teo, Matthew J. O'Shaughnessy, Sean M. McBride, Herbert A. Vargas, Howard I. Scher

    Drug development for noncastrate prostate cancer in a changed therapeutic landscape Drug development for noncastrate prostate cancer in a changed therapeutic landscape, Published online: 08 November 2017; doi:10.1038/nrclinonc.2017.177

    更新日期:2017-11-08
  • Tumour heterogeneity and resistance to cancer therapies
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-11-08
    Ibiayi Dagogo-Jack, Alice T. Shaw

    Tumour heterogeneity and resistance to cancer therapies Tumour heterogeneity and resistance to cancer therapies, Published online: 08 November 2017; doi:10.1038/nrclinonc.2017.166 NatureArticleSnippet(type=short-summary, markup= The onset of acquired resistance to treatment is virtually inevitable in patients with solid tumours. In this Review, the authors describe the role of tumour heterogeneity in the development of acquired resistance, potential treatment strategies that take into account the heterogeneity of patient's tumours, and how a better understanding of tumour heterogeneity might improve the outcomes of patients. , isJats=true)

    更新日期:2017-11-08
  • Immunotherapy: Gain beyond injection
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-25
    Diana Romero

    Immunotherapy: Gain beyond injection Nature Reviews Clinical Oncology, Published online: 25 October 2017; doi:10.1038/nrclinonc.2017.172

    更新日期:2017-10-30
  • Immunotherapy: Gain beyond injection
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-25
    Diana Romero

    Immunotherapy: Gain beyond injection Nature Reviews Clinical Oncology, Published online: 25 October 2017; doi:10.1038/nrclinonc.2017.172

    更新日期:2017-10-30
  • Haematological cancer: Extended EFS with rituximab
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-17
    Diana Romero

    Haematological cancer: Extended EFS with rituximab Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.168

    更新日期:2017-10-30
  • Imaging biomarkers exist and they underpin clinical decision-making
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-17
    John C. Waterton, Lisa M. McShane, James P. B. O'Connor

    Imaging biomarkers exist and they underpin clinical decision-making Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.167

    更新日期:2017-10-30
  • Breast Cancer: Abemaciclib effective in combination with aromatase inhibition
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-17
    Peter Sidaway

    Breast Cancer: Abemaciclib effective in combination with aromatase inhibition Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.169

    更新日期:2017-10-30
  • Drug development for noncastrate prostate cancer in a changed therapeutic landscape
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-17
    Min Yuen Teo, Matthew J. O'Shaughnessy, Sean M. McBride, Herbert A. Vargas, Howard I. Scher

    Drug development for noncastrate prostate cancer in a changed therapeutic landscape Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.160 Clinical trials are an essential aspect of drug development; however, in patients with non-castrate prostate cancer, the long natural history of the disease provides a major barrier to the introduction of new therapies. In this Review, the authors describe the potential of a novel, multi-arm, multistage, clinical trial project, with surrogate end points designed to fully reflect the effects of treatments, in transforming the treatment of patients with early stage prostate cancer, before the development of castration-resistant disease.

    更新日期:2017-10-30
  • Skin cancer: Propranolol limits melanoma recurrence
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-17
    David Killock

    Skin cancer: Propranolol limits melanoma recurrence Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.170

    更新日期:2017-10-30
  • Cholangiocarcinoma — evolving concepts and therapeutic strategies
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-10
    Sumera Rizvi, Shahid A. Khan, Christopher L. Hallemeier, Robin K. Kelley, Gregory J. Gores

    Cholangiocarcinoma — evolving concepts and therapeutic strategies Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.157 Cholangiocarcinoma, the second most common form of liver cancer after hepatocellular carcinoma, is a heterogeneous disease entity with a near-universal poor prognosis. Our understanding of the epidemiology and biology of cholangiocarcinoma is increasing, and importantly, potentially actionable molecular and immunological targets for novel therapies are increasingly being identified. Herein, the evolving developments in the epidemiology, pathogenesis, and management of cholangiocarcinoma are reviewed.

    更新日期:2017-10-30
  • Targeted therapy: ARIEL3 — broad benefit of PARP inhibitors in ovarian cancer
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-10
    David Killock

    Targeted therapy: ARIEL3 — broad benefit of PARP inhibitors in ovarian cancer Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.161

    更新日期:2017-10-30
  • Haematological cancer: Extended EFS with rituximab
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-17
    Diana Romero

    Haematological cancer: Extended EFS with rituximab Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.168

    更新日期:2017-10-17
  • Imaging biomarkers exist and they underpin clinical decision-making
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-17
    John C. Waterton, Lisa M. McShane, James P. B. O'Connor

    Imaging biomarkers exist and they underpin clinical decision-making Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.167

    更新日期:2017-10-17
  • Breast Cancer: Abemaciclib effective in combination with aromatase inhibition
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-17
    Peter Sidaway

    Breast Cancer: Abemaciclib effective in combination with aromatase inhibition Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.169

    更新日期:2017-10-17
  • Drug development for noncastrate prostate cancer in a changed therapeutic landscape
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-17
    Min Yuen Teo, Matthew J. O'Shaughnessy, Sean M. McBride, Herbert A. Vargas, Howard I. Scher

    Drug development for noncastrate prostate cancer in a changed therapeutic landscape Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.160 Clinical trials are an essential aspect of drug development; however, in patients with non-castrate prostate cancer, the long natural history of the disease provides a major barrier to the introduction of new therapies. In this Review, the authors describe the potential of a novel, multi-arm, multistage, clinical trial project, with surrogate end points designed to fully reflect the effects of treatments, in transforming the treatment of patients with early stage prostate cancer, before the development of castration-resistant disease.

    更新日期:2017-10-17
  • Skin cancer: Propranolol limits melanoma recurrence
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-10-17
    David Killock

    Skin cancer: Propranolol limits melanoma recurrence Nature Reviews Clinical Oncology, Published online: 17 October 2017; doi:10.1038/nrclinonc.2017.170

    更新日期:2017-10-17
  • Cholangiocarcinoma — evolving concepts and therapeutic strategies
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    Sumera Rizvi, Shahid A. Khan, Christopher L. Hallemeier, Robin K. Kelley, Gregory J. Gores

    Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Each subtype has a distinct epidemiology, biology, prognosis, and strategy for clinical management. The incidence of cholangiocarcinoma, particularly iCCA, has increased globally over the past few decades. Surgical resection remains the mainstay of potentially curative treatment for all three disease subtypes, whereas liver transplantation after neoadjuvant chemoradiation is restricted to a subset of patients with early stage pCCA. For patients with advanced-stage or unresectable disease, locoregional and systemic chemotherapeutics are the primary treatment options. Improvements in external-beam radiation therapy have facilitated the treatment of cholangiocarcinoma. Moreover, advances in comprehensive whole-exome and transcriptome sequencing have defined the genetic landscape of each cholangiocarcinoma subtype. Accordingly, promising molecular targets for precision medicine have been identified, and are being evaluated in clinical trials, including those exploring immunotherapy. Biomarker-driven trials, in which patients are stratified according to anatomical cholangiocarcinoma subtype and genetic aberrations, will be essential in the development of targeted therapies. Targeting the rich tumour stroma of cholangiocarcinoma in conjunction with targeted therapies might also be useful. Herein, we review the evolving developments in the epidemiology, pathogenesis, and management of cholangiocarcinoma.

    更新日期:2017-10-11
  • Targeted therapy: ARIEL3 — broad benefit of PARP inhibitors in ovarian cancer
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    David Killock

    Targeted therapy: ARIEL3 — broad benefit of PARP inhibitors in ovarian cancer Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.161

    更新日期:2017-10-11
  • Thyroid cancer: Cabozantinib effective in selected patients
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    Peter Sidaway

    Thyroid cancer: Cabozantinib effective in selected patients Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.163

    更新日期:2017-10-11
  • Lung Cancer: SABR effective against oligometastatic disease
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    Peter Sidaway

    Lung Cancer: SABR effective against oligometastatic disease Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.165

    更新日期:2017-10-11
  • Lung Cancer: Dacomitinib delays disease progression
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    Peter Sidaway

    Lung Cancer: Dacomitinib delays disease progression Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.162

    更新日期:2017-10-11
  • Breast cancer: LAG3 expression indicates favourable outcomes
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    Peter Sidaway

    Breast cancer: LAG3 expression indicates favourable outcomes Nature Reviews Clinical Oncology, Published online: 10 October 2017; doi:10.1038/nrclinonc.2017.164

    更新日期:2017-10-11
  • Radiomics: the bridge between medical imaging and personalized medicine
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    Philippe Lambin, Ralph T.H. Leijenaar, Timo M. Deist, Jurgen Peerlings, Evelyn E.C. de Jong, Janita van Timmeren, Sebastian Sanduleanu, Ruben T.H.M. Larue, Aniek J.G. Even, Arthur Jochems, Yvonka van Wijk, Henry Woodruff, Johan van Soest, Tim Lustberg, Erik Roelofs, Wouter van Elmpt, Andre Dekker, Felix M. Mottaghy, Joachim E. Wildberger, Sean Walsh

    Radiomics, the high-throughput mining of quantitative image features from standard-of-care medical imaging that enables data to be extracted and applied within clinical-decision support systems to improve diagnostic, prognostic, and predictive accuracy, is gaining importance in cancer research. Radiomic analysis exploits sophisticated image analysis tools and the rapid development and validation of medical imaging data that uses image-based signatures for precision diagnosis and treatment, providing a powerful tool in modern medicine. Herein, we describe the process of radiomics, its pitfalls, challenges, opportunities, and its capacity to improve clinical decision making, emphasizing the utility for patients with cancer. Currently, the field of radiomics lacks standardized evaluation of both the scientific integrity and the clinical relevance of the numerous published radiomics investigations resulting from the rapid growth of this area. Rigorous evaluation criteria and reporting guidelines need to be established in order for radiomics to mature as a discipline. Herein, we provide guidance for investigations to meet this urgent need in the field of radiomics.

    更新日期:2017-10-11
  • Patient-reported outcomes in cancer care — hearing the patient voice at greater volume
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    Thomas W. LeBlanc, Amy P. Abernethy

    Recording of patient-reported outcomes (PROs) enables direct measurement of the experiences of patients with cancer. In the past decade, the use of PROs has become a prominent topic in health-care innovation; this trend highlights the role of the patient experience as a key measure of health-care quality. Historically, PROs were used solely in the context of research studies, but a growing body of literature supports the feasibility of electronic collection of PROs, yielding reliable data that are sometimes of better quality than clinician-reported data. The incorporation of electronic PRO (ePRO) assessments into standard health-care settings seems to improve the quality of care delivered to patients with cancer. Such efforts, however, have not been widely adopted, owing to the difficulties of integrating PRO-data collection into clinical workflows and electronic medical-record systems. The collection of ePRO data is expected to enhance the quality of care received by patients with cancer; however, for this approach to become routine practice, uniquely trained people, and appropriate policies and analytical solutions need to be implemented. In this Review, we discuss considerations regarding measurements of PROs, implementation challenges, as well as evidence of outcome improvements associated with the use of PROs, focusing on the centrality of PROs as part of 'big-data' initiatives in learning health-care systems.

    更新日期:2017-10-11
  • Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    Kanaga Sabapathy, David P. Lane

    TP53, which encodes the tumour-suppressor protein p53, is the most frequently mutated gene across all cancer types. The presence of mutant p53 predisposes to cancer development, promotes the survival of cancer cells, and is associated with ineffective therapeutic responses and unfavourable prognoses. Despite these effects, no drug that abrogates the oncogenic functions of mutant p53 has yet been approved for the treatment of cancer. Current investigational therapeutic strategies are mostly aimed at restoring the wild-type activity of mutant p53, based on the assumption that all p53 mutants are functionally equal. Our increasing knowledge of mutant forms of p53, however, supports the antithetical hypothesis that not all p53 mutants have equivalent cellular effects; hence, a judicious approach to therapeutic targeting of mutant p53 is required. In this Review, we propose a categorization of the major classes of p53 mutants based on their functionality in tumour suppression and response to therapy. The emerging picture is that the mutations across TP53 form a 'rainbow of mutants', with varying degrees of functionality and different pathobiological consequences, necessitating the use of diverse therapeutic strategies to selectively target specific classes of mutation. The utility of this knowledge of TP53 mutations in developing selective therapeutic options, and in facilitating clinical decision-making is discussed.

    更新日期:2017-09-26
  • Drug therapy: Moving on up — from stage IV into stage III
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    David Killock

    Drug therapy: Moving on up — from stage IV into stage III Nature Reviews Clinical Oncology, Published online: 26 September 2017; doi:10.1038/nrclinonc.2017.159

    更新日期:2017-09-26
  • In the news
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    Diana Romero

    In the news Nature Reviews Clinical Oncology, Published online: 26 September 2017; doi:10.1038/nrclinonc.2017.158

    更新日期:2017-09-26
  • Colorectal cancer: Nivolumab effective against MSI tumours
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-16
    Peter Sidaway

    The outcomes of a phase II, single-arm study involving patients with microsatellite-unstable (MSI) metastatic colorectal cancer receiving treatment with nivolumab reveal high levels of effectiveness. In a heavily pretreated population, 23 patients (31% of the cohort) had an objective response, while 51 (69%) had disease

    更新日期:2017-09-20
  • Radiotherapy: Importantly, less is effective
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-09-12
    Diana Romero

    Whole-breast radiotherapy (WBRT), a standard of care for patients with early stage breast cancer, is associated with a reduced risk of recurrence and disease-related mortality. Clinical observations indicate that most local recurrences occur in the 'tumour bed' — the region of breast tissue closest to

    更新日期:2017-09-20
  • Prostate cancer: Chemotherapy outcomes similar in mCRPC
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-16
    Peter Sidaway

    The findings of a randomized phase III trial reveal similar levels of efficacy of 20 mg/m2 or 25 mg/m2 cabazitaxel, or 75 mg/m2 docetaxel (all regimens included prednisone) in men with metastatic castration-resistant prostate cancer (mCRPC). Patients in each

    更新日期:2017-09-20
  • Breast cancer: 10-year follow-up of the TEAM cohort reported
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-16
    Peter Sidaway

    Follow-up data after 10 years of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial, in which patients received either exemestrane for 5 years, or tamoxifen followed by exemestane for a total treatment duration of 5 years, confirm the durable efficacy of both approaches. Both groups of

    更新日期:2017-09-20
  • Targeted therapies: SOLO2 confirms olaparib maintenance in ovarian cancer
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-16
    Lisa Hutchinson

    Olaparib was the first PARP inhibitor approved for maintenance treatment following the practice-changing results of Study 19 — a randomized phase II trial of maintenance olaparib capsules versus placebo in patients with high-grade serous platinum-sensitive ovarian cancer. This trial demonstrated a significant treatment benefit in

    更新日期:2017-09-20
  • Immunotherapy: Adaptive resistance to CARs in glioma
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-08
    Lisa Hutchinson

    Glioblastoma (GBM) is one of the most common brain tumours and portends a poor prognosis; patient survival durations are typically

    更新日期:2017-09-20
  • Haematological cancer: Lenalidomide improves survival after ASCT
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-16
    Peter Sidaway

    A meta-analysis of patient-level data from three randomized controlled trials involving patients with newly diagnosed multiple myeloma indicates that lenalidomide maintenance therapy significantly improves the outcomes of patients undergoing autologous stem-cell transplantation (ASCT). In this analysis, patients receiving lenalidomide had a median progression-free survival duration

    更新日期:2017-09-20
  • Haematological cancer: After ibrutinib, CAR T cells induce responses
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-01
    Diana Romero

    The therapeutic landscape for chronic lymphocytic leukaemia (CLL) changed with the approval of the targeted agents ibrutinib and venetoclax; however, patients with progressive CLL after treatment with these agents have poor outcomes. Now, Cameron Turtle and collaborators have demonstrated promising antitumour activity of CD19-specific chimeric

    更新日期:2017-09-20
  • CNS cancer: Glioblastoma subtypes revisited
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-01
    Peter Sidaway

    Glioblastoma (GBM) was previously classified into four subtypes (classical, neural, proneural, and mesenchymal) based on transcriptional features; however, the original classification, to varying degrees, included the transcriptomes of tumour-associated nonmalignant cells in the analysis. Now, the findings of a comprehensive longitudinal analysis of the GBM

    更新日期:2017-09-20
  • Breast cancer: Short-term NAT reveals resistance
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-09-05
    David Killock

    Many breast-cancer-related deaths are attributable to recurrence of resected oestrogen receptor positive (ER+) tumours after adjuvant endocrine therapy. A study in 143 women with stage I–III ER+/HER2− breast cancer indicates that short-term neoadjuvant therapy (NAT) followed by genetic tumour profiling can not only uncover, but

    更新日期:2017-09-20
  • Breast cancer: Brain metastasis detectable in CTCs
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-22
    Peter Sidaway

    The presence of radiologically detectable metastases often indicates a poor prognosis in patients with breast cancer, highlighting a need for earlier detection. Now, new research reveals the presence of circulating tumour cells (CTCs) with a distinctly different transcriptomic signature to that of other breast cancer

    更新日期:2017-09-20
  • Prostate cancer: A new standard-of-care for advanced-stage disease
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-08
    Anis A. Hamid, Christopher J. Sweeney

    First-line, potent androgen blockade for patients with newly diagnosed, advanced-stage, castration-sensitive prostate cancer is confirmed as an effective strategy by data from the STAMPEDE and LATITUDE trials. Herein, we highlight the benefits, discuss caveats and consider the clinical care implications of these findings.

    更新日期:2017-09-20
  • Genetics: Taking single-cell transcriptomics to the bedside
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-01
    Sam Behjati, Muzlifah Haniffa

    Important biological questions can be addressed by interrogating the transcriptomes of cancer cells. In a recently published landmark study, Giustacchini and collaborators used a single-cell approach to analyse mRNA of cancer cells derived from patients with chronic myeloid leukaemia. Herein, we discuss how this approach could be used to address relevant clinical questions.

    更新日期:2017-09-20
  • Sarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes?
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-08
    Robin L. Jones, Khin Thway

    Patients with metastatic soft-tissue sarcoma can benefit from systemic therapy, but the best drug combinations for the different disease subtypes remain to be established. Recently, great emphasis has been placed on histology-based chemotherapy regimens. Herein, we discuss the results of a recently published study demonstrating that some of these regimens are not superior to standard-of-care chemotherapy in the neoadjuvant setting.

    更新日期:2017-09-20
  • Clinical utility of gene-expression signatures in early stage breast cancer
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-05-31
    Maryann Kwa, Andreas Makris, Francisco J. Esteva

    Breast cancer is a heterogeneous disease, with different subtypes having a distinct biological, molecular, and clinical course. Assessments of standard clinical and pathological features have traditionally been used to determine the use of adjuvant systemic therapy in patients with early stage breast cancer; however, the ability to identify those who will benefit from adjuvant chemotherapy remains a challenge, leading to the overtreatment of some patients. Advances in molecular medicine have substantially improved the accuracy of gene-expression profiling of breast tumours, resulting in improvements in the ability to predict a patient's risk of breast cancer recurrence and likely response to endocrine therapy and/or chemotherapy. These genomic assays, several of which are commercially available, have aided physicians in tailoring treatment decisions for patients at the individual level. Herein, we describe the available data on the clinical validity of the most widely available assays in patients with early stage breast cancer, with a focus on the development, validation, and clinical application of these assays, in addition to the anticipated outcomes of ongoing prospective trials. We also review data from comparative studies of these assays and from cost-effectiveness analyses relating to their clinical use.

    更新日期:2017-09-20
  • EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-04-11
    Tsukasa Shibue, Robert A. Weinberg

    The success of anticancer therapy is usually limited by the development of drug resistance. Such acquired resistance is driven, in part, by intratumoural heterogeneity — that is, the phenotypic diversity of cancer cells co-inhabiting a single tumour mass. The introduction of the cancer stem cell (CSC) concept, which posits the presence of minor subpopulations of CSCs that are uniquely capable of seeding new tumours, has provided a framework for understanding one dimension of intratumoural heterogeneity. This concept, taken together with the identification of the epithelial-to-mesenchymal transition (EMT) programme as a critical regulator of the CSC phenotype, offers an opportunity to investigate the nature of intratumoural heterogeneity and a possible mechanistic basis for anticancer drug resistance. In fact, accumulating evidence indicates that conventional therapies often fail to eradicate carcinoma cells that have entered the CSC state via activation of the EMT programme, thereby permitting CSC-mediated clinical relapse. In this Review, we summarize our current understanding of the link between the EMT programme and the CSC state, and also discuss how this knowledge can contribute to improvements in clinical practice.

    更新日期:2017-09-20
  • A further strategy to combat the high price of anticancer drugs
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-22
    Vinay Prasad, Kevin De Jesús, Sham Mailankody

    We thank Mr Gilbar for his interest in our Perspectives article (The high price of anticancer drugs: origin, implications, barriers, solutions. Nat. Rev. Clin. Oncol.14, 381–390 (2017)), and his expansion on the approaches to tackling the problem of the high prices

    更新日期:2017-09-20
  • A further strategy to combat the high price of anticancer drugs
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-08-22
    Peter J. Gilbar

    In their insightful Perspectives piece published in the June 2017 issue of this journal (The high price of anticancer drugs: origin, implications, barriers, solutions. Nat. Rev. Clin. Oncol.14, 381–390 (2017)), Prasad and colleagues discussed a number of possible solutions to the

    更新日期:2017-09-20
  • Evolution of lymphoma staging and response evaluation: current limitations and future directions
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-06-13
    Joel Cunningham, Sunil Iyengar, Bhupinder Sharma

    The accurate detection and precise assessment of therapeutic responses is critical to the optimal management of patients with lymphoma. Over the past 50 years, dramatic advances in technology have established imaging as the cornerstone of disease evaluation. However, the appropriate application of current techniques requires

    更新日期:2017-09-20
  • Targeted therapies: Survival ENDEAVORs
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 
    Lisa Hutchinson

    Targeted therapies: Survival ENDEAVORs Nature Reviews Clinical Oncology, Published online: 19 September 2017; doi:10.1038/nrclinonc.2017.155

    更新日期:2017-09-20
  • Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
    Nat. Rev. Clin. Oncol. (IF 20.693) Pub Date : 2017-09-19
    Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William Wierda, Cristina Gutierrez, Frederick L. Locke, Krishna V. Komanduri, Yi Lin, Nitin Jain, Naval Daver, Jason Westin, Alison M. Gulbis, Monica E. Loghin, John F. de Groot, Sherry Adkins, Suzanne E. Davis, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall

    Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematological and non-haematological malignancies. CAR-T-cell therapy can induce rapid and durable clinical responses, but is associated with unique acute toxicities, which can be severe or even fatal. Cytokine-release syndrome (CRS), the most commonly observed toxicity, can range in severity from low-grade constitutional symptoms to a high-grade syndrome associated with life-threatening multiorgan dysfunction; rarely, severe CRS can evolve into fulminant haemophagocytic lymphohistiocytosis (HLH). Neurotoxicity, termed CAR-T-cell-related encephalopathy syndrome (CRES), is the second most-common adverse event, and can occur concurrently with or after CRS. Intensive monitoring and prompt management of toxicities is essential to minimize the morbidity and mortality associated with this potentially curative therapeutic approach; however, algorithms for accurate and consistent grading and management of the toxicities are lacking. To address this unmet need, we formed a CAR-T-cell-therapy-associated TOXicity (CARTOX) Working Group, comprising investigators from multiple institutions and medical disciplines who have experience in treating patients with various CAR-T-cell therapy products. Herein, we describe the multidisciplinary approach adopted at our institutions, and provide recommendations for monitoring, grading, and managing the acute toxicities that can occur in patients treated with CAR-T-cell therapy.

    更新日期:2017-09-20
Some contents have been Reproduced with permission of the American Chemical Society.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
化学 · 材料 期刊列表